title: Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy.
abstract: Few therapeutic options are available for recurrent/metastatic head and neck cancer when progression occurs after initial chemotherapy. We analyzed retrospectively the efficacy of weekly Paclitaxel plus Cetuximab as second line of palliative chemotherapy. Patients with squamous carcinoma of head and neck with documented progression after initial treatment were enrolled. Tumor response was evaluated through the response evaluation criteria in solid tumor criteria. The retrospective analysis focused on overall survival (OS) and progression-free survival (PFS). Between 2008 and 2011, 33 consecutive patients were treated. A response rate of 55% was observed, with median response duration of 5.0 months (95% CI 3.3-11.1). The median PFS was 4.0 months (95% CI 2.9-5.0) and the median OS time was 10.0 months (95% CI 7.9-12.0). Acne-like rash/Folliculitis and chronic anemia were the most common adverse events. A weekly schedule of Paclitaxel plus Cetuximab is a promising regimen for patients with advanced head and neck cancer after failure of platinum-based therapy. Good tolerance of this treatment suggests that would be used in fragile patients.
authors: Department of Oncology, Hospital Clínic de Barcelona, Villaroel 170, 08036, Barcelona, Spain.
authors: Aaron E
authors: AE
authors: Sosa
authors: Juan J
authors: JJ
authors: Grau
authors: Luis
authors: L
authors: Feliz
authors: Verónica
authors: V
authors: Pereira
authors: Diego
authors: D
authors: Alcaraz
authors: Carmen
authors: C
authors: Muñoz-García
authors: Miguel
authors: M
authors: Caballero
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000068818:Cetuximab; D002945:Cisplatin; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D010166:Palliative Care; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D017239:Paclitaxel; D000068818:Cetuximab; D002945:Cisplatin
references: Acta Otolaryngol. 2009 Nov;129(11):1294-9
references: 19863327
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Head Neck. 2013 Feb;35(2):E52-4
references: 22144378
references: Ann Oncol. 2002 Jan;13(1):12-5
references: 11863092
references: Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24
references: 16149284
references: J Clin Oncol. 2005 Aug 20;23(24):5568-77
references: 16009950
references: Ann Oncol. 1997 May;8(5):445-9
references: 9233523
references: Nat Clin Pract Oncol. 2008 Dec;5(12):705-13
references: 18825142
references: Cancer. 2006 Jan 1;106(1):106-11
references: 16329139
references: Clin Cancer Res. 2000 Dec;6(12):4874-84
references: 11156247
references: Cancer. 2008 Jun 15;112(12):2710-9
references: 18481809
references: Anticancer Drugs. 2011 Aug;22(7):621-5
references: 21131821
references: N Engl J Med. 2008 Sep 11;359(11):1116-27
references: 18784101
references: Anticancer Drugs. 2010 Jun;21(5):553-8
references: 20220515
references: Ann Oncol. 2011 May;22(5):1078-1087
references: 21048039
references: Biologics. 2010 Aug 09;4:173-85
references: 20714355
references: Ann Oncol. 2012 Apr;23(4):1016-22
references: 21865152
references: Arch Otolaryngol Head Neck Surg. 2007 Nov;133(11):1143-8
references: 18025320